Equity Overview
Price & Market Data
Price: $0.155
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $785,542
Daily Volume: 0
Performance Metrics
1 Week: -22.45%
1 Month: -8.76%
3 Months: -63.80%
6 Months: -74.15%
1 Year: -95.98%
YTD: -9.30%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.